Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250011/S005

ProVee System for BPH

Proverum, Ltd. · Decision date Nov 3, 2026

MEDTECHLEDGER EXPLANATIONP250011/S005

What did the FDA approve?

The FDA recorded an approval decision dated 2026-11-03 for P250011/S005, a PMA supplement to the ProVee System for BPH submitted by Proverum, Ltd. The supplement is classified as a Real-Time Process review with the stated reason Change Design/Components/Specifications/Material. The recorded statement identifies the changed item as changes to the OmniVision CMOS Camera Cube.

This action covers the supplement only; it is not a new approval of the entire ProVee System. The device category is listed as a permanent or semi-permanent prostatic urethral stent, with Gastroenterology and Urology as the specialty and product code MER. The source record includes no supporting documents, so the scope of the camera cube change, its effect on the finished device, and any conditions of approval remain unknown.

FDA approval order statement

changes to the OmniVision CMOS Camera Cube
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
Nov 3, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250011/S005
Regulatory pathway
PMA supplement
Product code
MER
Decision code
APPR
Decision date
Nov 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.

Product code
MER
FDA device class
3

For the original device and its historical approval scope, see PMA P250011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250011 · Original PMA

    ProVee System for BPH

  2. P250011/S005 received

    Application receipt date recorded by FDA.

  3. P250011/S005 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250011

Product / regulatory recordCompanyPathwayDecision dateSource
Proverum, Ltd.PMA approvalDec 9, 2025FDA
Proverum, Ltd.PMA supplementSep 24, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Proverum, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records